Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
Kee-Jong Hong 4 Articles
Ebola Hemorrhagic Fever and the Current State of Vaccine Development
Joo Eun Hong, Kee-Jong Hong, Woo Young Choi, Won-Ja Lee, Yeon Hwa Choi, Chung-Hyeon Jeong, Kwang-il Cho
Osong Public Health Res Perspect. 2014;5(6):378-382.   Published online December 31, 2014
DOI: https://doi.org/10.1016/j.phrp.2014.09.006
  • 2,125 View
  • 15 Download
  • 5 Citations
AbstractAbstract PDF
Current Ebola virus outbreak in West Africa already reached the total number of 1,323 including 729 deaths by July 31st. the fatality is around 55% in the southeastern area of Guinea, Sierra Leone, Liberia, and Nigeria. The number of patients with Ebola Hemorrhagic Fever (EHF) was continuously increasing even though the any effective therapeutics or vaccines has not been developed yet. The Ebola virus in Guinea showed 98% homology with Zaire Ebola Virus.Study of the pathogenesis of Ebola virus infection and assess of the various candidates of vaccine have been tried for a long time, especially in United States and some European countries. Even though the attenuated live vaccine and DNA vaccine containing Ebola viral genes were tested and showed efficacy in chimpanzees, those candidates still need clinical tests requiring much longer time than the preclinical development to be approved for the practical treatment.It can be expected to eradicate Ebola virus by a safe and efficient vaccine development similar to the case of smallpox virus which was extinguished from the world by the variola vaccine.

Citations

Citations to this article as recorded by  
  • Recent developments and strategies of Ebola virus vaccines
    Ashish Ranjan Sharma, Yeon-Hee Lee, Sudarshini Nath, Sang-Soo Lee
    Current Opinion in Pharmacology.2021; 60: 46.     CrossRef
  • Predictive Effects of Novelty Measured by Temporal Embeddings on the Growth of Scientific Literature
    Jiangen He, Chaomei Chen
    Frontiers in Research Metrics and Analytics.2018;[Epub]     CrossRef
  • Social network analysis and modeling of cellphone-based syndromic surveillance data for Ebola in Sierra Leone
    Jia B. Kangbai
    Asian Pacific Journal of Tropical Medicine.2016; 9(9): 851.     CrossRef
  • El desarrollo de nuevas vacunas
    Fernando González-Romo, Juan J. Picazo
    Enfermedades Infecciosas y Microbiología Clínica.2015; 33(8): 557.     CrossRef
  • Out of Africa, Into Global Health Security Agenda
    Hae-Wol Cho, Chaeshin Chu
    Osong Public Health and Research Perspectives.2014; 5(6): 313.     CrossRef
Serological Correlate of Protection in Guinea Pigs for a Recombinant Protective Antigen Anthrax Vaccine Produced from Bacillus brevis
Jeong-Hoon Chun, On-Jee Choi, Min-Hee Cho, Kee-Jong Hong, Won Keun Seong, Hee-Bok Oh, Gi-Eun Rhie
Osong Public Health Res Perspect. 2012;3(3):170-176.   Published online June 30, 2012
DOI: https://doi.org/10.1016/j.phrp.2012.07.006
  • 2,202 View
  • 22 Download
  • 10 Citations
AbstractAbstract PDF
Objective Recombinant protective antigen (rPA) is the active pharmaceutical ingredient of a second generation anthrax vaccine undergoing clinical trials both in Korea and the USA. By using the rPA produced from Bacillus brevis pNU212 expression system, correlations of serological immune response to anthrax protection efficacy were analyzed in a guinea pig model.
Methods
Serological responses of rPA anthrax vaccine were investigated in guinea pigs that were given single or two injections (interval of 4 weeks) of various amounts of rPA combined with aluminumhydroxide adjuvant. Guinea pigs were subsequently challenged by the intramuscular injection with 30 half-lethal doses (30LD50) of virulent Bacillus anthracis spores. Serumantibody titerswere determined by anti-PA IgGELISA and the ability of antibodies to neutralize the cytotoxicity of lethal toxin on J774A.1 cell was measured through the toxin neutralizing antibody (TNA) assay.
Results
To examine correlations between survival rate and antibody titers, correlation between neutralizing antibody titers and the extent of protection was determined. Toxin neutralization titers of at least 1176 were sufficient to confer protection against a dose of 30LD50 of virulent anthrax spores of the H9401 strain. Such consistency in the correlation was not observed from those antibody titers determined by ELISA.
Conclusion
Neutralizing-antibody titers can be used as a surrogate marker.

Citations

Citations to this article as recorded by  
  • A putative exosporium lipoprotein GBAA0190 of Bacillus anthracis as a potential anthrax vaccine candidate
    Jun Ho Jeon, Yeon Hee Kim, Kyung Ae Kim, Yu-Ri Kim, Sun-Je Woo, Ye Jin Choi, Gi-eun Rhie
    BMC Immunology.2021;[Epub]     CrossRef
  • Construction of a bivalent vaccine against anthrax and smallpox using the attenuated vaccinia virus KVAC103
    Deok Bum Park, Bo-Eun Ahn, Hosun Son, Young-Ran Lee, Yu-Ri Kim, Su Kyoung Jo, Jeong-Hoon Chun, Jae-Yon Yu, Myung-Min Choi, Gi-eun Rhie
    BMC Microbiology.2021;[Epub]     CrossRef
  • Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis
    Sean M. Kelly, Kristina R. Larsen, Ross Darling, Andrew C. Petersen, Bryan H. Bellaire, Michael J. Wannemuehler, Balaji Narasimhan
    Vaccine.2021; 39(29): 3862.     CrossRef
  • Current Status and Trends in Prophylaxis and Management of Anthrax Disease
    Vladimir Savransky, Boris Ionin, Joshua Reece
    Pathogens.2020; 9(5): 370.     CrossRef
  • Anthrax prevention through vaccine and post-exposure therapy
    Manish Manish, Shashikala Verma, Divya Kandari, Parul Kulshreshtha, Samer Singh, Rakesh Bhatnagar
    Expert Opinion on Biological Therapy.2020; 20(12): 1405.     CrossRef
  • A therapeutic human antibody against the domain 4 of the Bacillus anthracis protective antigen shows protective efficacy in a mouse model
    Bo-Eun Ahn, Hee-Won Bae, Hae-Ri Lee, Sun-Je Woo, Ok-Kyu Park, Jun Ho Jeon, Jungchan Park, Gi-eun Rhie
    Biochemical and Biophysical Research Communication.2019; 509(2): 611.     CrossRef
  • Vaccines against anthrax based on recombinant protective antigen: problems and solutions
    Olga A. Kondakova, Nikolai A. Nikitin, Ekaterina A. Evtushenko, Ekaterina M. Ryabchevskaya, Joseph G. Atabekov, Olga V. Karpova
    Expert Review of Vaccines.2019; 18(8): 813.     CrossRef
  • A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes
    Theodor Chitlaru, Ma'ayan Israeli, Shahar Rotem, Uri Elia, Erez Bar-Haim, Sharon Ehrlich, Ofer Cohen, Avigdor Shafferman
    Vaccine.2017; 35(44): 6030.     CrossRef
  • Expression and refolding of the protective antigen of Bacillus anthracis: A model for high-throughput screening of antigenic recombinant protein refolding
    María Elisa Pavan, Esteban Enrique Pavan, Fabián Martín Cairó, María Julia Pettinari
    Revista Argentina de Microbiología.2016; 48(1): 5.     CrossRef
  • Protein- and DNA-based anthrax toxin vaccines confer protection in guinea pigs against inhalational challenge withBacillus cereusG9241
    John Palmer, Matt Bell, Christian Darko, Roy Barnewall, Andrea Keane-Myers
    Pathogens and Disease.2014; : n/a.     CrossRef
In vivo Noninvasive Small Animal Molecular Imaging
Hyewon Youn, Kee-Jong Hong
Osong Public Health Res Perspect. 2012;3(1):48-59.   Published online December 31, 2011
DOI: https://doi.org/10.1016/j.phrp.2012.02.002
  • 2,078 View
  • 12 Download
  • 13 Citations
AbstractAbstract PDF
The remarkable efforts that are made on molecular imaging technologies demonstrate its potential importance and range of applications. The generation of disease-specific animal models, and the developments of target-specific probes and genetically encoded reporters are another important component. Continued improvements in the instrumentation, the identification of novel targets and genes, and the availability of improved imaging probes should be made. Multimodal imaging probes should provide easier transitions between laboratory studies, including small animal studies and clinical applications. Here, we reviewed basic strategies of noninvasive in vivo imaging methods in small animals to introducing the concept of molecular imaging.

Citations

Citations to this article as recorded by  
  • Molecular imaging of tumor-associated macrophages in cancer immunotherapy
    Xiaoying Li, Ruike Wang, Yangnan Zhang, Shuangze Han, Yu Gan, Qi Liang, Xiaoqian Ma, Pengfei Rong, Wei Wang, Wei Li
    Therapeutic Advances in Medical Oncology.2022; 14: 175883592210761.     CrossRef
  • In vivo molecular and single cell imaging
    Seongje Hong, Siyeon Rhee, Kyung Oh Jung
    BMB Reports.2022; 55(6): 267.     CrossRef
  • Evaluation of the Small-animal Nano Scan PET/CT System using 89Zr
    Khalid Alzimami, Sitah Alanazi, Magdi Gannam, Ahmad Alanazi, Ibrahim Aljamaz, Suliman Alyanbawi, Basem Alotaibi, Yousif Almalki, Abdelmoneim Sulieman, Salem Sassi
    Current Medical Imaging Formerly Current Medical I.2021; 17(2): 296.     CrossRef
  • Development of an embedded multimodality imaging platform for onco-pharmacology using a smart anticancer prodrug as an example
    Florian Raes, Serigne Moussa Badiane, Brigitte Renoux, Sébastien Papot, Stéphanie Lerondel, Alain Le Pape
    Scientific Reports.2020;[Epub]     CrossRef
  • Noninvasive Tracking of Hematopoietic Stem Cells in a Bone Marrow Transplant Model
    Fernando A. Oliveira, Mariana P. Nucci, Igor S. Filgueiras, João M. Ferreira, Leopoldo P. Nucci, Javier B. Mamani, Fernando Alvieri, Lucas E. B. Souza, Gabriel N. A. Rego, Andrea T. Kondo, Nelson Hamerschlak, Lionel F. Gamarra
    Cells.2020; 9(4): 939.     CrossRef
  • Genetically Encoded Reporter Genes for MicroRNA Imaging in Living Cells and Animals
    Yingzhuang Song, Zhijing Xu, Fu Wang
    Molecular Therapy - Nucleic Acids.2020; 21: 555.     CrossRef
  • The Molecular Imaging of Natural Killer Cells
    Mariya Shapovalova, Sean R. Pyper, Branden S. Moriarity, Aaron M. LeBeau
    Molecular Imaging.2018; 17: 153601211879481.     CrossRef
  • Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based Immunotherapies
    Prakash Gangadaran, Byeong-Cheol Ahn
    Frontiers in Immunology.2017;[Epub]     CrossRef
  • Hepatocellular Carcinoma Cells Carrying a Multimodality Reporter Gene for Fluorescence, Bioluminescence, and Magnetic Resonance Imaging In Vitro and In Vivo
    Xiaoxiao Qin, Xiaojun Hu, Chun Wu, Mingyue Cai, Zhengran Li, Lina Zhang, Liteng Lin, Wensou Huang, Kangshun Zhu
    Academic Radiology.2016; 23(11): 1422.     CrossRef
  • Prospects on Time-Domain Diffuse Optical Tomography Based on Time-Correlated Single Photon Counting for Small Animal Imaging
    Yves Bérubé-Lauzière, Matteo Crotti, Simon Boucher, Seyedrohollah Ettehadi, Julien Pichette, Ivan Rech
    Journal of Spectroscopy.2016; 2016: 1.     CrossRef
  • DNA nanomaterials for preclinical imaging and drug delivery
    Dawei Jiang, Christopher G. England, Weibo Cai
    Journal of Controlled Release.2016; 239: 27.     CrossRef
  • Fluorophore-NanoLuc BRET Reporters Enable Sensitive In Vivo Optical Imaging and Flow Cytometry for Monitoring Tumorigenesis
    Franz X. Schaub, Md. Shamim Reza, Colin A. Flaveny, Weimin Li, Adele M. Musicant, Sany Hoxha, Min Guo, John L. Cleveland, Antonio L. Amelio
    Cancer Research.2015; 75(23): 5023.     CrossRef
  • GFP-taggedE. colishows bacterial distribution in mouse organs: pathogen tracking using fluorescence signal
    Pil-Gu Park, Min-Hee Cho, Gi-eun Rhie, Haeseul Jeong, Hyewon Youn, Kee-Jong Hong
    Clinical and Experimental Vaccine Research.2012; 1(1): 83.     CrossRef
Ingenol Protects Human T Cells From HIV-1 Infection
Kee-Jong Hong, Hak Sung Lee, Yeong-shik Kim, Sung Soon Kim
Osong Public Health Res Perspect. 2011;2(2):109-114.   Published online June 30, 2011
DOI: https://doi.org/10.1016/j.phrp.2011.07.001
  • 1,946 View
  • 17 Download
  • 10 Citations
AbstractAbstract PDF
Objectives
Many natural compounds have been investigated as drug candidates to prevent human immunodeficiency virus (HIV) with low cytotoxicity. We tested whether ingenol from Euphorbia ingens exerts anti-HIV effects in human T cell lines.
Methods
and Results Ingenol effectively maintained high cell viability (CD50, >1 mM) in H9 and MT4 T cells. The efficacy of ingenol to inhibit HIV-1 infection was dose dependent. ED50 for 100 and 200 TCID50 of HIV-1 was 5.06 and 16.87 μM, respectively. Gag p24 antigen production in ingenol-treated MT4 cells was reduced by 24.5% on day 6 post-infection. While p24 antigen was reduced in ingenol-treated cells, levels of cytokines such as TNF-α and IL-6 and chemokines such as RANTES and MCP-1 were increased. dUTP level related to late apoptotic events was increased on day 2 post-infection of HIV by ingenol treatment, whereas expression of annexin V was unchanged. Reduced levels of iNOS and ZAP-70 after HIV infection were recovered by ingenol treatment.
Conclusion
Ingenol helps T cells to survive longer against viremia after HIV-1 infection, without exerting cytotoxic effects. Ingenol can be considered a safe and efficacious candidate for immune-boosting therapy for AIDS patients.

Citations

Citations to this article as recorded by  
  • A review of the ethnomedicinal, pharmacology, cytotoxicity and phytochemistry of the genus Euphorbia in southern Africa
    E.J. Mavundza, R. Street, H. Baijnath
    South African Journal of Botany.2022; 144: 403.     CrossRef
  • South African plants with nematicidal activity against root-knot nematodes: A review
    F.N. Makhubu, M.C. Khosa, L.J. McGaw
    South African Journal of Botany.2021; 139: 183.     CrossRef
  • Systematic characterization of metabolic profiles of ingenol in rats by UPLC-Q/TOF-MS and NMR in combination with microbial biotransformation
    Si-Jia Xiao, Shan-Shan Li, Bin Xie, Wei Chen, Xi-Ke Xu, Xian-Peng Zu, Yun-Heng Shen
    RSC Advances.2021; 11(60): 37752.     CrossRef
  • Structure-Activity-Relationship and Mechanistic Insights for Anti-HIV Natural Products
    Ramandeep Kaur, Pooja Sharma, Girish K. Gupta, Fidele Ntie-Kang, Dinesh Kumar
    Molecules.2020; 25(9): 2070.     CrossRef
  • Modified ingenol semi-synthetic derivatives from Euphorbia tirucalli induce cytotoxicity on a large panel of human cancer cell lines
    Viviane A. O Silva, Marcela N. Rosa, Olga Martinho, Amilcar Tanuri, João Paulo Lima, Luiz F. Pianowski, Rui M. Reis
    Investigational New Drugs.2019; 37(5): 1029.     CrossRef
  • Natural product-derived compounds in HIV suppression, remission, and eradication strategies
    Raymond J. Andersen, Fidele Ntie-Kang, Ian Tietjen
    Antiviral Research.2018; 158: 63.     CrossRef
  • Biphasic Effects of Ingenol 3,20-Dibenzoate on the Erythropoietin Receptor: Synergism at Low Doses and Antagonism at High Doses
    Jin-Gyo Oh, Young-Won Chin, Sung-Jo Kim, Jong Min Choi, Sang Kyum Kim, Hee Eun Kang, Tae-Hwe Heo
    Molecular Pharmacology.2015; 88(2): 392.     CrossRef
  • LC-MS2-Based dereplication of Euphorbia extracts with anti-Chikungunya virus activity
    Louis-Félix Nothias-Scaglia, Vincent Dumontet, Johan Neyts, Fanny Roussi, Jean Costa, Pieter Leyssen, Marc Litaudon, Julien Paolini
    Fitoterapia.2015; 105: 202.     CrossRef
  • Reactivation of latent HIV-1 by new semi-synthetic ingenol esters
    Diego Pandeló José, Koen Bartholomeeusen, Rodrigo Delvecchio da Cunha, Celina Monteiro Abreu, Jan Glinski, Thais Barbizan Ferreira da Costa, Ana Flávia Mello Bacchi Rabay, Luiz Francisco Pianowski Filho, Lech W. Dudycz, Udaykumar Ranga, Boris Matija Peter
    Virology.2014; 462-463: 328.     CrossRef
  • Dual Role of Novel Ingenol Derivatives from Euphorbia tirucalli in HIV Replication: Inhibition of De Novo Infection and Activation of Viral LTR
    Celina M. Abreu, Sarah L. Price, Erin N. Shirk, Rodrigo D. Cunha, Luiz F. Pianowski, Janice E. Clements, Amilcar Tanuri, Lucio Gama, Cheryl A. Stoddart
    PLoS ONE.2014; 9(5): e97257.     CrossRef

PHRP : Osong Public Health and Research Perspectives